<DOC>
	<DOCNO>NCT00001951</DOCNO>
	<brief_summary>The human ovary produce male sex hormone ( androgen ) female sex hormone ( estrogen ) . Currently , androgen include hormone replacement therapy woman premature ovarian failure . Present hormone replacement therapy ( HRT ) design treat woman experience ovarian failure menopause ( around age 50 ) . However , 1 % woman experience premature failure ovaries age 40 . There study conduct determine proper hormone replacement therapy young woman . Some research suggest usual menopausal hormone replacement therapy adequate protect young woman premature ovarian failure develop osteoporosis . Women premature ovarian failure abnormally low level androgens circulate blood . This may contribute increase risk osteoporosis . This study compare two treatment plan woman premature ovarian failure . Treatment plan one physiological estrogen hormone replacement . Treatment plan two physiological estrogen hormone replacement plus androgen . The study attempt determine plan beneficial woman relation osteoporosis heart disease . The hormone contain patch give place patch patient 's skin . The patch design deliver amount hormone would normally produce ovary young woman . The success treatment measure periodically check density patient 's bone leg ( femoral neck bone ) . Researchers take initial ( baseline ) measurement bone density begin treatment year , 3 additional year , treatment . The study also consider bone density spine , bone turnover , heart disease risk factor , psychological state .</brief_summary>
	<brief_title>Hormone Replacement Young Women With Premature Ovarian Failure</brief_title>
	<detailed_description>Present menopausal hormone replacement therapy regimen design woman experience ovarian failure around age 50 . At least 1 % woman , however , experience premature ovarian failure age 40 , study establish optimal hormone replacement therapy regimens young woman . Available evidence suggest usual menopausal hormone replacement therapy adequate protect young woman premature ovarian failure develop osteoporosis . Women premature ovarian failure abnormally low circulate androgen level , may contribute risk osteoporosis . We plan compare physiological estrogen replacement physiological estrogen plus androgen replacement young woman premature ovarian failure determine regimen beneficial bone mineral density metabolic parameter relate risk cardiovascular disease . This study employ transdermal estradiol testosterone `` patch '' design deliver amount sex steroid normally produce ovary young woman physiological manner . Women premature ovarian failure randomize receive either estradiol plus placebo patch estradiol plus testosterone patch . Both group receive cyclic progestin treatment . A group age-matched woman normal ovarian function serve contemporaneous control bone density study measure . The primary outcome parameter femoral neck bone mineral density , assessed baseline , 1 , 2 , 3 year treatment . Other outcome parameter include lumbar spine bone mineral density , marker bone turnover , cardiovascular disease risk factor , cognitive function .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Menopause , Premature</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients karyotypically normal spontaneous premature ovarian failure ( define screen protocol 91CH0127 , i.e . woman least 4 month amenorrhea , two FSH level 40 mIU/ml , least one month apart , normal 46 , XX karotype , diagnosed premature ovarian failure prior age 40 ) age 18 42 year candidate . EXCLUSION CRITERIA : General : Smokers ( 2 cigarette per day ) . Alcohol user ( 2 drink alcohol per day ) . Body mass index ( BMI , kg/m ( 2 ) ) great equal 30 less equal 19 . Previous history hip fracture active hip pathology . Abnormalities hip preclude assessment bone mineral density . Major dermatologic disorder , history skin sensitivity adhesive bandage , tape transdermal matrix patch . Hirsutism score great 8 . Acne score great 1 . Hysterectomy Baseline free testosterone ( FT ) level normal range ( great 6.3 pg/ml current essay ) and/or SHBG level less 36 nmol/L . Medical use : Any prior treatment past 6 month know affect bone estrogen ( i.e. , calcitonin , biphosphonates , fluoride , anabolic steroid , testosterone , herbal therapy contain androstenedione , DHEA ) . Current and/or past use : diuretic , anticoagulant ( heparin , Coumadin ) , glucocorticoid drug , gonadotropinreleasing hormone agonist antagonist therapy , chemotherapy . Medical history : Anorexia nervosa , hyperprolactinemia , insulindependent diabetes , Cushing 's syndrome , gastrectomy , osteogenesis imperfecta , mastocytosis , rheumatoid arthritis , longterm parenteral nutrition , hemolytic anemia , hemochromatosis thalassemia , ankylose spondylitis , multiple myeloma , Vitamin D deficiency , Paget 's disease , primary hyperparathyroidism , hyperthyroidism , hypothyroidism , cancer major illness . Contraindications hormone replacement therapy : Thromboembolic event associate previous estrogen use History endometrial cancer hyperplasia History breast cancer Hypertriglyceridemia ( fast triglyceride level great 500 mg/dL ) LDL great 190mg/dl Patients take `` statin '' Serum Alkaline phosphatase great equal 2X upper limit normal Serum GGT greather equal 2X upper limit normal Abnormal value two hepatic panel test Undiagnosed Vaginal Bleeding Known sensitivity agent Note : We include patient premature ovarian failure antidepressant medication , since today 's common antidepressant medication ( Prozac ) major import cognitive function . However , note whether medication . CONTROL SELECTION CRITERIA : Healthy nonpregnant regularly menstruating woman ( cycle 21 35 day ) , nonsmoker , nonalcohol user , medication , use nonhormonal contraceptive method ( i.e . barrier method contraception , sterilization ) intention conceive within follow 3 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Bone</keyword>
	<keyword>Cognition</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Mood</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Ovarian Failure</keyword>
	<keyword>Hormone Replacement Therapy</keyword>
	<keyword>POF</keyword>
	<keyword>Premature Ovarian Failure</keyword>
</DOC>